BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20062919)

  • 1. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
    Schulz S; Sibbing D; Braun S; Morath T; Mehilli J; Massberg S; Byrne RA; Schömig A; Kastrati A
    Am Heart J; 2010 Aug; 160(2):355-61. PubMed ID: 20691843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
    Ergelen M; Uyarel H; Osmonov D; Ayhan E; Akkaya E; Soylu O; Orhan AL; Sayar N; Bozbay M; Turer A; Yildirim E; Yekeler I
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):33-41. PubMed ID: 19736213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
    Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
    Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schömig A; Kastrati A
    Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
    Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
    Roy P; Bonello L; Torguson R; Okabe T; Pinto Slottow TL; Steinberg DH; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Mar; 103(6):801-5. PubMed ID: 19268735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
    Geisler T; Langer H; Wydymus M; Göhring K; Zürn C; Bigalke B; Stellos K; May AE; Gawaz M
    Eur Heart J; 2006 Oct; 27(20):2420-5. PubMed ID: 17005534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.